Proposed merger partners Akorn, Hi-Tech have business overlaps in lidocaine jelly
Akorn and Nasdaq-listed pharmaceutical rival Hi-Tech Pharmacal, whose $640 million deal is under extended antitrust review, have competing businesses in a type of topical anesthetic.Akorn and Nasdaq-listed pharmaceutical rival Hi-Tech Pharmacal, whose $640...To view the full article, register now.
Already a subscriber? Click here to view full article